The short version of AOD-9604 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-13 and is reviewed periodically as new material appears.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Prevention trials look for ways to prevent disease in people who have never had the disease or to prevent a disease from returning. These approaches may include drugs, vitamins or other micronutrients, vaccines, or lifestyle changes. Screening trials test for ways to identify certain diseases or health conditions. Diagnostic trials are conducted to find better tests or procedures for diagnosing a particular disease or condition. Treatment trials test experimental drugs, new combinations of drugs, or new approaches to surgery or radiation therapy. Quality of life trials (supportive care trials) evaluate how to improve comfort and quality of care for people with a chronic illness. Genetic trials are conducted to assess the prediction accuracy of genetic disorders making a person more or less likely to develop a disease. Epidemiological trials have the goal of identifying the general causes, patterns or control of diseases in large numbers of people. Compassionate use trials or expanded access trials provide partially tested, unapproved therapeutics to a small number of patients who have no other realistic options. Usually, this involves a disease for which no effective therapy has been approved, or a patient who has already failed all standard treatments and whose health is too compromised to qualify for participation in randomized clinical trials. Usually, case-by-case approval must be granted by both the FDA and the pharmaceutical company for such exceptions.
Racecadotril, also known as acetorphan, is an antidiarrheal medication which acts as a peripheral enkephalinase inhibitor. Unlike other opioid medications used to treat diarrhea, which reduce intestinal motility, racecadotril has an antisecretory effect — it reduces the secretion of water and electrolytes into the intestine. It is available in France (where it was first introduced in ~1990) and other European countries (including Germany, Italy, the United Kingdom, Spain, Portugal, Poland, Finland, Slovakia, Russia and Czechia ) as well as most of South America and some South East Asian countries (including China, India and Thailand), but not in the United States. It is sold under the tradename Hidrasec, among others. Thiorphan is the active metabolite of racecadotril, which exerts the bulk of its inhibitory actions on enkephalinases.
An aquaretic is a novel class of drug that is used to promote aquaresis, the excretion of water without electrolyte loss. Strictly speaking, aquaretics are not diuretics but are sometimes classified as such. Aquaresis is preferable to diuresis in the treatment of hyponatremia.
When a compound has limited solubility in water it is common practice (in the pharmaceutical industry, for example) to determine pKa values in a solvent mixture such as water/dioxane or water/methanol, in which the compound is more soluble. In the example shown at the right, the pKa value rises steeply with increasing percentage of dioxane as the dielectric constant of the mixture is decreasing. A pKa value obtained in a mixed solvent cannot be used directly for aqueous solutions. The reason for this is that when the solvent is in its standard state its activity is defined as one. For example, the standard state of water:dioxane mixture with 9:1 mixing ratio is precisely that solvent mixture, with no added solutes. To obtain the pKa value for use with aqueous solutions it has to be extrapolated to zero co-solvent concentration from values obtained from various co-solvent mixtures. These facts are obscured by the omission of the solvent from the expression that is normally used to define pKa, but pKa values obtained in a given mixed solvent can be compared to each other, giving relative acid strengths. The same is true of pKa values obtained in a particular non-aqueous solvent such a DMSO. A universal, solvent-independent, scale for acid dissociation constants has not been developed, since there is no known way to compare the standard states of two different solvents.
About 60% of all casualties were civilians, who died as a result of disease, starvation, genocide (in particular, the Holocaust), and aerial bombing. The former Soviet Union and China suffered the most casualties. Estimates place deaths in the Soviet Union at around 23 million, while China suffered about 10 million. No country lost a greater portion of its population than Poland: approximately 5.6 million, or 16%, of its pre-war population of 34.8 million died. The Holocaust (which roughly means "burnt whole") was the deliberate and systematic murder of millions of Jews and other "unwanted" groups during World War II by the Nazi regime in Germany. Several differing views exist regarding whether it was intended to occur from the war's beginning or if the plans for it came about later. Regardless, persecution of Jews extended well before the war even started, such as during Kristallnacht (Night of Broken Glass). The Nazis used propaganda to great effect to stir up anti-Semitic feelings within ordinary Germans. After World War II, Europe was informally split into Western and Soviet spheres of influence. Western Europe later aligned as NATO, and Eastern Europe as the Warsaw Pact. There was a shift in power from Western Europe and the British Empire to the two new superpowers, the United States and the Soviet Union. These two rivals would later face off in the Cold War. In Asia, the defeat of Japan led to its democratization. China's civil war continued through and after the war, eventually resulting in the establishment of the People's Republic of China.
Sources: en.wikipedia.org
== Musical style == In an interview with MTV in 2006, vocalist Taylor said that Come What(ever) May was a return to the roots of the band, stating it is "a lot more from the spirit of what the band started with in 1992". He noted that some songs were "very atmospheric" while others maintained "the hard rock and the heavy stuff". Jon Wiederhorn of MTV said that "for every thrash riff there's a tunefully grungy passage, for every flailing guitar line there's a rock-radio hook." When talking about the track "30/30-150", he said parts are "bludgeoning, barbed and heavy" while others are "soaring and triumphant" with the production of Raskulinecz helping to balance the album's heaviness with its radio-accessibility. Come What(ever) May's lyrics include themes of "pain, pleasure, happiness, and grief". The diversity in subjects is evident throughout the album; songs including "Come What(ever) May" were politically influenced while the track "Socio" is about "social anxiety attacks" that Taylor suffered. "Zzyzx Rd" is a love song written to Taylor's wife for helping him in his struggles against alcoholism and contemplation of suicide. "I've never written anything like that before, but it was very important for me to tell the world not only how much she saved me, but how much she means to me," said Taylor. Taylor said there is a common thread with the lyrics throughout the album, saying that they are "about never forgetting where you came from, who you are and why you do this."
An example is copper-64, which has 29 protons, and 35 neutrons, which decays with a half-life of 12.7004(13) hours. This isotope has one unpaired proton and one unpaired neutron, so either the proton or the neutron can decay to the other particle, which has opposite isospin. This particular nuclide (though not all nuclides in this situation) is more likely to decay through beta plus decay (61.52(26)%) than through electron capture (38.48(26)%). The excited energy states resulting from these decays which fail to end in a ground energy state, also produce later internal conversion and gamma decay in almost 0.5% of the time.
Progesterone, a progestogen, is the other of the two major sex hormones in women. It is mainly involved in the regulation of the female reproductive system, the menstrual cycle, pregnancy, and lactation. The non-reproductive effects of progesterone are fairly insignificant. Unlike estrogens, progesterone is not known to be involved in the development of female secondary sexual characteristics, and hence is not believed to contribute to feminization in women. One area of particular interest in terms of the effects of progesterone in women is breast development. Estrogens are responsible for the development of the ductal and connective tissues of the breasts and the deposition of fat into the breasts during puberty in girls. Conversely, high levels of progesterone, in conjunction with other hormones such as prolactin, are responsible for the lobuloalveolar maturation of the mammary glands during pregnancy. This allows for lactation and breastfeeding after childbirth. Although progesterone causes the breasts to change during pregnancy, the breasts undergo involution and revert to their pre-pregnancy composition and size after the cessation of breastfeeding. Every pregnancy, lobuloalveolar maturation occurs again anew. There are two types of progestogens: progesterone, which is the natural and bioidentical hormone in the body; and progestins, which are synthetic progestogens. There are dozens of clinically used progestins.
Over the next two years, Raymond worked on a colossal project that he considered to be his life’s work: La Basilique de Sainte Sophie (Αγία Σοφία) de Constantinople (The Basilica of Hagia Sophia of Constantinople). This was published in 1933. He used his knowledge of the monument, the work and notes left by his father, the architect Marc Raymond, and a substantial number of photographs of the inside of the building. The undeniable originality of the drawings (ink, watercolour, gold-leaf and silver paintings) is that they represent Hagia Sophia before the Muslims covered it with lime mosaics. Only one drawing of Hagia Sophia, relating to the period when Alexandre Raymond took on his work, 1931, existed. The entire work totals some 88 representations of various sizes. The drawings are complemented by the text describing Hagia Sophia (Αγία Σοφία) written by Procopius of Caesarea, the anonymous text of the Holy Wisdom (also known as Holy Sophia, Divine Wisdom), and a historic and descriptive text from the author.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.